Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Navamedic ASA ( (DE:N1A) ) is now available.
Navamedic ASA has successfully completed the acquisition of dne pharma AS’s business, including its product portfolio and key employees, for up to NOK 225 million. This acquisition marks a strategic expansion into addiction treatment, enhancing Navamedic’s market presence in the Nordics and selected European markets. The acquisition is financed through a combination of new debt and a rights issue, with support from Nordea Bank and DNB Carnegie. This move is expected to strengthen Navamedic’s position in the rapidly growing field of opioid substitution therapy.
More about Navamedic ASA
Navamedic ASA is a Nordic pharmaceutical company focused on providing high-quality prescription, consumer health, and hospital products. The company addresses public health concerns such as obesity, Parkinson’s disease, and gastrointestinal issues, and is known for its strong local insight and market access capabilities across the Nordics and Benelux regions. Navamedic has been listed on the Oslo Stock Exchange since 2006 and is headquartered in Oslo, Norway.
Average Trading Volume: 13,603
Current Market Cap: NOK393.9M
For a thorough assessment of N1A stock, go to TipRanks’ Stock Analysis page.